1. Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
   Beatrice T. Wang et al, 2021, Molecular Cancer Therapeutics CrossRef
2. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis
   T He et al, 2014, Oncogene CrossRef
3. Core Fucosylation Mediated by the FucT-8 Enzyme Affects TRAIL-Induced Apoptosis and Sensitivity to Chemotherapy in Human SW480 and SW620 Colorectal Cancer Cells
   Rubén López-Cortés et al, 2023, International Journal of Molecular Sciences CrossRef
4. Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes
   Rongrong Fu et al, 2024, Pharmaceutical Development and Technology CrossRef
5. Co-delivery of chemotherapeutics and proteins for synergistic therapy
   Chaoliang He et al, 2016, Advanced Drug Delivery Reviews CrossRef
6. TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo
   Hong Zhu et al, 2017, Molecular Medicine Reports CrossRef
7. Targeting death receptors for TRAIL by agents designed by Mother Nature
   Sahdeo Prasad et al, 2014, Trends in Pharmacological Sciences CrossRef
8. Antimicrobial Peptides as New Combination Agents in Cancer Therapeutics: A Promising Protocol against HT-29 Tumoral Spheroids
   Mina Raileanu et al, 2020, International Journal of Molecular Sciences CrossRef
9. The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells
   Hong Zhu et al, 2013, BioMed Research International CrossRef